Conversations in Lung Cancer Research

Mar 06 2025 49 ep. 26 mins 24
Conversations in Lung Cancer Research Podcast artwork

Welcome to Conversations in Lung Cancer Research, presented by TOGA, your go-to podcast for in-depth insights into lung cancer. Tune in for conversations with leading experts, inspiring stories, and the latest updates on clinical trials. Stay informed and empowered in the fight against lung cancer.

  Health & Fitness
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


Exploring EGFR Exon 20 Insertion Mutations

Mar 06 2025 30 mins  
In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore, along with thoracic oncologists Dr. Malinda Itchins and A/Prof Surein Arulananda, delve into the characteristics, detection, and treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. The podcast discusses recent advances, the efficacy of various treatments including small molecule tyrosine

From Clinical Research to Leadership: A Conversation with Prof. Michael Boyer

Feb 05 2025 34 mins  
In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore interviews Prof Michael Boyer, AM about his extensive career in medical oncology and his current role as CEO of Chris O'Brien Lifehouse. They discuss his early interest in oncology, the influential mentors in his career, and the evolution of lung cancer treatment and research. Michael shares his perspectives

Introducing Conversations in Lung Cancer Research - Trailer

Feb 04 2025 1 mins  
In this introductory episode, Associate Professor Mel Moore, medical oncologist and education chair at TOGA, announces the evolution of TOGA podcasts to 'Conversations in Lung Cancer Research.' The podcast will continue to deliver the latest breakthroughs in lung cancer research while expanding to include deeper dives and engaging discussions with experts in thoracic oncology. Li

Navigating Resistance in ALK-Positive NSCLC Patients on TKI Therapy

Dec 12 2024 26 mins  
We have witnessed incredible advances in therapy since ALK was discovered in 2007, starting from the pivotal PROFILE 1001 study of crizotinib in advanced ALK positive NSCLC to present day where we now have five approved targeted agents, with increasing potency, selectivity and CNS activity with each successive generation of drug. Despite these advances in therapy, the emergence of

Hit It With Your Best Shot- The Case for IO in Early-Stage NSCLC in a Once in a Lifetime World

Dec 01 2024 27 mins  
Our latest podcast explores the case for IO in early-stage NSCLC in our once in a lifetime world – the current Australian context. We review the medical oncology and surgical perspective of the current evidence for clinical benefit and what we have available in Australia. As clinicians, we are trained to give our best treatment up front, so patient discussion is important in an e

Large-Cell Neuroendocrine Carcinoma of the Lung (LCNEC): Challenges in Diagnosis and Treatment

Nov 14 2024 23 mins  
In this episode, we discuss the clinical and diagnostic markers when identifying a rare sub type of NSCLC, large-cell neuroendocrine carcinomas (LC-NEC), and provide insights into the management of these patients and future treatment developments. Associate Professor Rachel Wong, Deputy Director Oncology Eastern Health and Medical Oncologist at Epworth East in Melbourne is joined

Management of Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Sep 30 2024 18 mins  
In this episode, we dive into the latest survival data from the ADRIATIC trial, as presented at ASCO 2024, which could change the treatment landscape for LS-SCLC. Joining us are leading experts in oncology Zarnie Lwin, Susan Harden and Wei-Sen Lam. Together, they explore the significance of the ADRIATIC trial results, debate the role of prophylactic cranial irradiation (PCI) in the

NTRK1, 2,3 And Other Rare Mutations In NSCLC

Aug 29 2024 21 mins  
In this TOGA podcast, we provide an overview of the treatment options for rare subtypes of oncogene driven NSCLC that are now readily identified in the MBS-reimbursed small gene panel including NTRK1, 2,3 and other rare mutations in NSCLC. The importance of testing all patients is discussed as well as what to do when resistance occurs. Associate Professor Steven Kao, Medical Onco

Decoding Perioperative Immunotherapy In NSCLC

Jul 24 2024 21 mins  
In this TOGA podcast, we provide an overview of the recent neoadjuvant, adjuvant, and perioperative IO data, the options and considerations for treatment and the current reimbursement landscape. Dr Pei Ni Ding, Medical Oncologist from Westmead and Nepean Hospitals Sydney, is joined by Dr Samantha Bowyer, Medical Oncologist from Sir Charles Gairdner Hospital in Perth and Mr Naveed A

Access to New Medicines: Which Surrogate Endpoints Matter

Jun 19 2024 24 mins  
Do we need to evolve the bar on evidence required for drug reimbursement? The gold standard endpoint for assessing the benefit of anti-cancer drugs has been overall survival (OS) however, more recently, there has been a trend toward using surrogate clinical trial endpoints such as progression free survival (PFS) and event-free survival (EFS). As treatments improve and patients are